Who is sponsoring NCT07501234?

NCT07501234 is sponsored by Mitrassist Lifesciences Limited Co., Ltd..

What drugs are being tested in NCT07501234?

Interventions in NCT07501234: MitraFix® Transcatheter Mitral Valve System.

What condition does NCT07501234 study?

NCT07501234 studies Mitral Regurgitation (MR).

Is NCT07501234 still recruiting?

NCT07501234 is currently recruiting now. Last updated 30 March 2026.

Last reviewed 2026-03-30 · How we verify

NCT07501234: MITRA-EFS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Feasibility Study of the MitraFix® Transcatheter Mitral Valve System

Recruiting now NA Last updated 30 March 2026

What this trial tests

NA trial testing MitraFix® Transcatheter Mitral Valve System in Mitral Regurgitation (MR) in 5 participants. Currently enrolling.

Timeline

23 March 2026

Primary endpoint
23 March 2028

23 October 2028

Quick facts

Lead sponsor	Mitrassist Lifesciences Limited Co., Ltd.
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	device feasibility
Enrollment	5
Start date	23 March 2026
Primary completion	23 March 2028
Estimated completion	23 October 2028
Sites	1 location across China

Drugs / interventions tested

MitraFix® Transcatheter Mitral Valve System

Conditions studied

Mitral Regurgitation (MR) — all drugs for Mitral Regurgitation (MR) →

Sponsor

Mitrassist Lifesciences Limited Co., Ltd. — full company profile →

Who can join

18 and older, any sex, with Mitral Regurgitation (MR). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this early feasibility clinical trial is to test a new device called the MitraFix® Transcatheter Mitral Valve System. It aims to learn if the device is safe and if it can help adults who have a severe leaky heart valve (mitral regurgitation). This study is for people who are at high risk for traditional open-heart surgery. The main questions it aims to answer are: Is the MitraFix system safe for participants? Can the device be successfully placed in the heart? Does the device help reduce the valve leak and improve daily life? Participants will: Receive the MitraFix valve through a small tube inserted into a vein in the leg. Visit the clinic for heart tests, walking tests, and health checks for up to one year after the procedure.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Mitral Regurgitation (MR)

Currently open trials in the same condition.

NCT07197736 — DELINEATE-Prospective · recruiting
NCT06816888 — Impact of Automatic Prompts in Echocardiographic Reports on Referral to Cardiology · NA · active not recruiting
NCT06876883 — MItral Regurgitation Risk Assessment and CLinical modElling · recruiting
NCT07045753 — The Prospective Segeberg Registry for Mitral Transcatheter Edge-to-Edge Repair · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07501234 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mitrassist Lifesciences Limited Co., Ltd.
Last refreshed: 30 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07501234.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing